AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12630984
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 9 days
Trial: 8738947
Drug: Adequate antibiotic
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate antibiotic therapy
Trial: 1662033
Drug: Sinorphan 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan 10 mg
Trial: 1662033
Drug: Sinorphan 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan 20 mg
Trial: 1662033
Drug: Sinorphan 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan 40 mg
Trial: 1662033
Drug: Sinorphan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan (all doses)
Trial: 31617335
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg body weight) administered at 11 a.m. or 6 p.m. for 24 weeks
Trial: 31617335
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) administered at 11 a.m. or 6 p.m. for 24 weeks
Trial: 29657029
Drug: Pharmacologic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacologic administration of FGF21
Trial: 26891181
Drug: Topiramate in
RxNorm normalized name: Product containing topiramate in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate in rs2832407*CC genotype
Trial: 24262513
Drug: Corinthian Raisins
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corinthian Raisins (CR) consumption (36 g/d, replacing snacks with similar energy density twice daily)
Trial: 24262513
Drug: Corinthian Raisins
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corinthian Raisins (CR) consumption (36 g/d)
Trial: 22101624
Drug: Tezosentan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (3 mg/h for 2-3 h)
Trial: 16640173
Drug: Latest antihypertensive
RxNorm normalized name: testosterone enanthate Injectable Solution [Delatest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latest antihypertensive drugs
Trial: 7743798
Drug: Ciprofloxacin dosing
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin dosing regimen compatible with home use: two drops of 0.3% ciprofloxacin every 4 h over a 24‐h period (Group 1)
Trial: 7743798
Drug: Ciprofloxacin dosing
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin dosing regimen applied by a trained professional: two drops of Ciloxan every 15 min over a 4‐h period (Group 2)
Trial: 7743798
Drug: Ciprofloxacin dosing
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin dosing regimen applied by a trained professional with corneas abraded (Group 3)
Trial: 1903409
Drug: Oral nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nitroglycerin (0.6 mg)
Trial: 6168124
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg p.o/day for 5 days
Trial: 31498919
Drug: RASB discontinuation
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: RASB discontinuation
Trial: 28659162
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus herbal medicine and health education
Trial: 19324953
Drug: Cross-shift decrease
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-shift decrease in PEF of 5 L.min(‐1)
Trial: 17785973
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion (SI) of piperacillin/sulbactam (4/1 g every 8 h)
Trial: 17785973
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of piperacillin/sulbactam (8/2 g per 24 h after loading dose)
Trial: 12589521
Drug: Pindolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (20 mg orally)
Trial: 12589521
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of buspirone and pindolol
Trial: 12589521
Drug: Buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30 mg orally) with Pindolol (20 mg orally)
Trial: 10783215
Drug: SAK42D 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAK42D 15 mg
Trial: 10783215
Drug: SAK42D 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAK42D 30 mg
Trial: 10783215
Drug: SAK42D 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAK42D 45 mg
Trial: 9816275
Drug: PALA 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA 125 mg/m2
Trial: 9816275
Drug: PALA 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA 250 mg/m2
Trial: 9816275
Drug: PALA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA 500 mg/m2
Trial: 9816275
Drug: PALA 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA 1000 mg/m2
Trial: 9816275
Drug: 5-FU 400
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400 mg/m2
Trial: 9816275
Drug: DP 50
RxNorm normalized name: Dextropropoxyphene 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP 50 mg/m2
Trial: 9816275
Drug: 5-FU dose
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU dose escalation
Trial: 1576631
Drug: clindamycin+gentamicin (C+G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clindamycin+gentamicin (C+G)
Trial: 2829267
Drug: ZK 93,426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 93,426 (0.01 mg/kg)
Trial: 30475969
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g protein · kg‐1 · d‐1
Trial: 30475969
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g protein · kg‐1 · d‐1
Trial: 28222641
Drug: Rapid genotyping-guided
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid genotyping-guided treatment (GG)
Trial: 26135562
Drug: ivacaftor (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivacaftor (150 mg)
Trial: 20394809
Drug: MS-CN (control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-CN (control, no medication, MS provocation)
Trial: 20394809
Drug: CN (control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN (control, no medication, no MS provocation)
Trial: 16507196
Drug: prilocaine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prilocaine 1% 40 mL (G1)
Trial: 16507196
Drug: prilocaine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prilocaine 1% 30 mL and ropivacaine 0.75% 10 mL (G2)
Trial: 16507196
Drug: prilocaine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prilocaine 1% 20 mL and ropivacaine 0.75% 20 mL (G3)
Trial: 16507196
Drug: ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.75% 40 mL (G4)
Trial: 14645194
Drug: 17beta-E(2) (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-E(2) (4 mg/day) from day 20 until next cycle day 2
Trial: 14645194
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no E(2) pre-treatment)
Trial: 14645194
Drug: 17beta-E(2) (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-E(2) (4 mg/day)
Trial: 8622848
Drug: Holmium:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holmium:YAG laser treatment
Trial: 24742939
Drug: Home-based constraint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based constraint induced therapy (CIT)
Trial: 18630766
Drug: Bilateral single-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral single-site thoracic paravertebral block with 25 mL of bupivacaine 0.25% with epinephrine 1:200.000
Trial: 18630766
Drug: Placebo (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25 mL of 0.9% NaCl)
Trial: 11812424
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of water orally administered 30 minutes before verteporfin infusion
Trial: 11812424
Drug: No hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hydration before therapy
Trial: 1600686
Drug: Verapamil hydrochloride
RxNorm normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil hydrochloride extended-release pellet-filled capsule (240 mg) sprinkled on applesauce
Trial: 1600686
Drug: Verapamil hydrochloride
RxNorm normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil hydrochloride extended-release pellet-filled capsule swallowed intact
Trial: 3902237
Drug: ibuprofen-codeine phosphate
RxNorm normalized name: codeine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen-codeine phosphate combination
Trial: 27544904
Drug: Reboxetine 4
RxNorm normalized name: reboxetine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 4 mg monotherapy
Trial: 27544904
Drug: Reboxetine 4
RxNorm normalized name: reboxetine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 4 mg combined with desmopressin
Trial: 25377946
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium (PAM) short-term treatment (PAM-S) for 2 weeks
Trial: 25377946
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium (PAM) long-term treatment (PAM-L) for 10 weeks
Trial: 25377946
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium (PAM) treatment
Trial: 23525511
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI)
Trial: 23525511
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI) with a spacer
Trial: 1971636
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (ampicillin, gentamicin, metronidazole)
Trial: 6993259
Drug: Anti-lymphocytic globulin
RxNorm normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-lymphocytic globulin (ALG) 1 g daily for 5 days
Trial: 6993259
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with corticosteroids
Trial: 28237866
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and bevacizumab (CAP-B) maintenance therapy
Trial: 28237866
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and bevacizumab (CAP-B) maintenance therapy in patients with complete or partial response
Trial: 21425519
Drug: Preventive intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive intervention (watchful waiting, minimally supported CBT-based self-help intervention, problem-solving treatment, referral to a primary care physician for medication if required)
Trial: 17289236
Drug: Depot antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot antipsychotics (DA)
Trial: 17289236
Drug: Antipsychotic polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic polypharmacy (APP), depot antipsychotics (DA), and clozapine
Trial: 9770089
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion (Disoprifusor-TCI)
Trial: 9770089
Drug: Manually Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually Controlled Infusion
Trial: 28693998
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 or 150 mg, given every 2 weeks
Trial: 28693998
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 or 150 mg
Trial: 26048739
Drug: Stationary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stationary and tablet platforms
Trial: 21058940
Drug: Propofol-alfentanil combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-alfentanil combination sedation (group PA)
Trial: 15119171
Drug: Needling at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needling at bilateral Neiguan (PC 6) plus oral administration of mexiletine
Trial: 15119171
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of mexiletine
Trial: 11702162
Drug: Iobitridol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iobitridol (300 mg/ml), 120 ml
Trial: 11702162
Drug: Iohexol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (300 mg/ml), 120 ml
Trial: 2500141
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mitomycin C 15 mg/m2 plus DSM 360 mg administered into the hepatic artery (group I)
Trial: 2500141
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mitomycin C 15 mg/m2 (group II)
Trial: 28224449
Drug: Regadenoson 0.4
RxNorm normalized name: REGADENOSON 0.4MG/5ML INJ VIL 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadenoson 0.4 mg during recovery (Ex-Reg)
Trial: 28224449
Drug: Regadenoson 0.4
RxNorm normalized name: REGADENOSON 0.4MG/5ML INJ VIL 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadenoson 0.4 mg 1 hour after inadequate exercise (Regadenoson)
Trial: 26195123
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin (100 mg)
Trial: 26195123
Drug: Placebo (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.6 g glycerin suppository)
Trial: 24299497
Drug: Rivastigmine capsules
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules for 8 months
Trial: 24299497
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsules for 8 months
Trial: 16545638
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg folic acid daily
Trial: 12943949
Drug: Clomipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (150 mg/day) plus Lithium Carbonate (750 mg/day)
Trial: 12943949
Drug: Clomipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (150 mg/day) plus Placebo
Trial: 10683055
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (100 mg/wk intramuscularly), no exercise
Trial: 8151563
Drug: Aminobenzoate potassium
RxNorm normalized name: Aminobenzoate Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminobenzoate potassium (KPAB) 12 g/day
Trial: 3277606
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc administration
Trial: 26270340
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) at 0.1 mg/kg/day, target 5‐8 ng/ml
Trial: 26270340
Drug: Ciclosporin A
RxNorm normalized name: Ciclosporin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin A (CSA) with target 70‐150 ng/ml
Trial: 21415807
Drug: Active Individual
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Individual Therapy (Control)
Trial: 1489187
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg clarithromycin
Trial: 1489187
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg clarithromycin
Trial: 1489187
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clarithromycin
Trial: 1489187
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clarithromycin
Trial: 1489187
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg clarithromycin
Trial: 1489187
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg clarithromycin
Trial: 3735223
Drug: Cefaclor 125
RxNorm normalized name: cefaclor 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 125 mg tds for three days
Trial: 3735223
Drug: Cefaclor 125
RxNorm normalized name: cefaclor 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 125 mg tds for seven days
Trial: 27814258
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser treatment (1 W, 10 Hz for 60 seconds, unfocused at 0.5 cm distance)
Trial: 27814258
Drug: GaAlAs laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAlAs laser treatment (40 mW; 4 J/cm²; 15 seconds per point on 4 points)
Trial: 27814258
Drug: 2% neutral
RxNorm normalized name: Perfect Choice 2% Neutral Topical Gel (Vanilla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% neutral fluoride gel application (60 seconds)
Trial: 24452706
Drug: Robot-assisted arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted arm group therapy (RAGT) + individual arm therapy (IAT) for 30 minutes each, per workday for four weeks.
Trial: 24452706
Drug: Individual arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual arm therapy (IAT) for 2x30 minutes, per workday for four weeks.
Trial: 24452706
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of treatment with RAGT.
Trial: 18425236
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet (approximately 30 g)
Trial: 18425236
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet plus 10 g of hydrolyzed partially guar-gum
Trial: 10582548
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet with one daily fish meal (3.6 g omega3 fatty acids per day)
Trial: 8947318
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group in clinical trials of medications for alcoholism treatment
Trial: 1880222
Drug: Volmax (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volmax (4 mg) administered after a meal
Trial: 1880222
Drug: Proventil Repetabs
RxNorm normalized name: Proventil Repetabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proventil Repetabs (4 mg) administered after a meal
Trial: 1880222
Drug: Volmax (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volmax (4 mg) administered in fasting state
Trial: 1880222
Drug: Proventil Repetabs
RxNorm normalized name: Proventil Repetabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proventil Repetabs (4 mg) administered in fasting state
Trial: 6852412
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg orally and intravenously)
Trial: 31763269
Drug: Nasal decongestant
RxNorm normalized name: Nasal Decongestant
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal decongestant drops
Trial: 25644148
Drug: Aprepitant in
RxNorm normalized name: aprepitant Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant in combination with conventional 5HT3 blocker-based prophylaxis
Trial: 25644148
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (conventional 5HT3 blocker-based prophylaxis only)
Trial: 21956278
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy + Basic treatment
Trial: 17969890
Drug: Pabing Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pabing Recipe 1 (PR1) plus Madopa tablets